Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

Anti-apoptotic effects of erythropoietin in experimental myocardial infarction and ischemia-reperfusion injury suggest potential for therapeutic benefit in patients with acute MI. Before the therapeutic potential of rHuEpo in acute MI can be tested in large clinical trials, more information on the effects of short-term rHuEpo on platelet function are needed. Accordingly, the current proposal aims to determine the effects of 3 doses of rHuEpo (100U/kg, 200U/kg and 400U/kg daily for 3 days) on platelet function and other safety measures in healthy subjects.

Specific Aim: To determine the effects of three ascending doses of rHuEpo vs. placebo on in vivo and in vitro platelet function in healthy subjects treated with aspirin and clopidogrel.

Hypotheses to be tested: 1) 1) Short-term administration of rHuEpo does not alter bleeding time responses to aspirin and clopidogrel when compared with placebo. 2) Short-term administration does not alter in vitro platelet aggregation responses to aspirin and clopidogrel when compared with placebo.

Inclusion criteria

• Age 21-40 years
• Able and willing to provide written informed consent
• Bleeding time <10 minutes

Exclusion criteria

• Any chronic medical disease
• Chronic or frequent over-the-counter or prescription medication use
• Hemoglobin >15 gm/dl for both genders or <13 gm/dl (men) or <12 gm/dl (women)
• Platelet count >400,000/µl or <150,000/µl
• Blood pressure > 140/90 mmHg